Sort
261,768 grants matching “gene therapy”
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
$1,048,134Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Hepato/Renal Fibrocystic Diseases Core Center (UAB HRFDCC)
$1,048,120Bradley K. Yoder · University Of Alabama At Birmingham · P30 · FY2013 · DK
MOLECULAR CLASSIFICATION OF B-CELL LYMPHOMA
$1,047,887University Of Nebraska Medical Center · U01 · FY2000 · CA
Profiling cancer neoantigen repertoires and validating immunotherapy targets
$1,047,882Martin W McIntosh · Fred Hutchinson Cancer Research Center · U01 · FY2014 · CA
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,047,825Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,047,789Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Proteomic Predictors of Clinical Outcome of Targeted Therapies in Prostate Cancer
$1,047,738David B Agus · Stanford University · U54 · FY2009 · CA
Curation of genetic defects causing combined immunodeficiency and infections in children
$1,047,682Ivan Kingyue Chinn · Baylor College Of Medicine · U24 · FY2025 · HD
Epigenetic mechanisms regulating the Igf2/H19 and Kcnq1 locus
$1,047,577Karl Eric Pfeifer · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2016 · HD
Exploiting Riboswitch Sensors to Reveal Antibiotics Uptake and Retention in Gram Negative Bacteria
$1,047,570Ronald R Breaker · Yale University · R01 · FY2022 · AI
Genes And Gene Products As Immunoadjuvants
$1,047,553Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Interventional approaches for restoring vision
$1,047,522Anand Swaroop · National Eye Institute · ZIA · FY2018 · EY
Clinical Trials of Immunotherapies for Childhood Cancer
$1,047,388Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Bone marrow-targeted extracellular vesicles as a novel non-viral gene editor delivery platform
$1,047,299Jonathan N Thon · Strm.Bio, Inc. · R44 · FY2023 · TR
Preclinical Development of an NT3-expressing HSV Vector
$1,047,123David J. Fink · University Of Michigan At Ann Arbor · U01 · FY2013 · NS
Ultrasensitive Nanofluidic Devices for Genomic Analysis
$1,046,910Stephen R Quake · Stanford University · R01 · FY2008 · HG
Drug Development for Prostate Cancer and other Metastatic Processes
$1,046,884William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
NON-HUMAN PRIMATE MODELS FOR EVALUATION OF AIDS THERAPIE
$1,046,786Henry M. Jackson Fdn For The Adv Mil/Med · N01 · FY2000 · AI
Cytokines in AIDS and Cancer
$1,046,735George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
$1,046,640Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2022 · CA
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
$1,046,639Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2023 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2017 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2021 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2016 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2020 · CA